CCS
IONS icon

Crosspoint Capital Strategies’s Ionis Pharmaceuticals IONS Stock Holding History

Crosspoint Capital Strategies’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-600
Closed -$37K – 460
2015
Q4 		$37K Buy
+600
New +$32.4K 0.01% 484
2014
Q2 		– Sell
-100
Closed -$4K – 571
2014
Q1 		$4K Buy
+100
New +$4.85K ﹤0.01% 604

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Crosspoint Capital Strategies's IONS Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Ionis Pharmaceuticals (IONS) in Q1 2016, closing a stake of 600 shares — an estimated $37K sold.

Crosspoint Capital Strategies first reported a position in IONS in Q1 2014 and held it in 2 quarters. The position peaked at $37K in Q4 2015. 314 funds tracked by Wall St. Rank hold IONS as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining Ionis Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 600 Ionis Pharmaceuticals shares in Q1 2016, an estimated $37K.
  • Crosspoint Capital Strategies first reported a position in Ionis Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Crosspoint Capital Strategies's Ionis Pharmaceuticals position peaked at $37K in Q4 2015.
  • 314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.